{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:39:38Z","timestamp":1761709178840},"reference-count":116,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.tips.2015.11.009","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T13:32:00Z","timestamp":1450704720000},"page":"207-219","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes"],"prefix":"10.1016","volume":"37","author":[{"given":"Sivaram","family":"Pillarisetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2015.11.009_bib0005","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dci15-0012","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"38","author":"Fox","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2015.11.009_bib0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus","volume":"141","author":"Selvin","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1210\/jc.2005-2084","article-title":"Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia","volume":"91","author":"Ginsberg","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2015.11.009_bib0020","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2015.11.009_bib0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0035","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes. ACCORD Study Group","volume":"364","author":"Gerstein","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0040","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(11)60698-3","article-title":"Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial","volume":"378","author":"Griffin","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2015.11.009_bib0045","first-page":"CD008143","article-title":"Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus","volume":"11","author":"Hemmingsen","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2015.11.009_bib0050","doi-asserted-by":"crossref","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.tips.2015.11.009_bib0055","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2015.11.009_bib0060","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0065","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2015.11.009_bib0070","first-page":"1563","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"29","author":"Ginsberg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0075","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2337\/diaclin.22.4.169","article-title":"Targeting plasma glucose: preprandial versus postprandial","volume":"22","author":"Shrot","year":"2004","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.tips.2015.11.009_bib0085","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/diacare.24.10.1734","article-title":"Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes","volume":"24","author":"Erlinger","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2015.11.009_bib0090","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetes patients","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2015.11.009_bib0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-8227(99)00061-3","article-title":"Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels","volume":"46","author":"Soonthornpun","year":"1999","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tips.2015.11.009_bib0100","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)12131-1","article-title":"Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe","volume":"354","author":"Anon.","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2015.11.009_bib0105","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s001250100020","article-title":"Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence","volume":"44","author":"Bonora","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.tips.2015.11.009_bib0110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.numecd.2006.05.006","article-title":"Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update","volume":"16","author":"Ceriello","year":"2006","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2015.11.009_bib0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4158\/EP.12.S1.47","article-title":"Postprandial hyperglycemia and cardiovascular disease","volume":"12","author":"Gerich","year":"2006","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.tips.2015.11.009_bib0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11892-009-0088-4","article-title":"Postprandial lipoproteins and cardiovascular disease risk in diabetes mellitus","volume":"10","author":"Enkhmaa","year":"2010","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.tips.2015.11.009_bib0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0002-9343(82)90580-0","article-title":"Glucose intolerance and nine-year mortality in Japanese men in Hawaii","volume":"72","author":"Yano","year":"1982","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0130","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.2337\/diacare.15.10.1328","article-title":"Relationship of postload plasma glucose to mortality with 19-yr follow-up Comparison of one versus two plasma glucose measurements in the Chicago Peoples Gas Company Study","volume":"15","author":"Vaccaro","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2015.11.009_bib0135","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s001250050617","article-title":"Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up","volume":"39","author":"Hanefeld","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.tips.2015.11.009_bib0140","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/jc.2005-1005","article-title":"Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study","volume":"91","author":"Cavalot","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2015.11.009_bib0145","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.2337\/dc10-2414","article-title":"Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study","volume":"34","author":"Cavalot","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2015.11.009_bib0150","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/db10-1032","article-title":"Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy","volume":"59","author":"Rizza","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2015.11.009_bib0155","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.metabol.2005.03.024","article-title":"Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus","volume":"54","author":"Henkel","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.tips.2015.11.009_bib0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2337\/diaspect.17.3.183","article-title":"Glucose Metabolism and regulation: beyond insulin and glucagon","volume":"17","author":"Aronoff","year":"2004","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.tips.2015.11.009_bib0165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00400639","article-title":"Failure of glucagon suppression contributes to postprandial hyperglycemia in IDDM","volume":"38","author":"Dinneen","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.tips.2015.11.009_bib0170","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.mcna.2011.06.002","article-title":"Insulin resistance: the link between obesity and cardiovascular disease","volume":"95","author":"Reaven","year":"2011","journal-title":"Med. Clin. North. Am."},{"key":"10.1016\/j.tips.2015.11.009_bib0175","doi-asserted-by":"crossref","first-page":"11J","DOI":"10.1016\/S0002-9149(99)00351-3","article-title":"Epidemiology of insulin resistance and its relation to coronary artery disease","volume":"84","author":"Haffner","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.tips.2015.11.009_bib0180","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(75)92375-2","article-title":"The essential role of glucagon in the pathogenesis of diabetes mellitus","volume":"1","author":"Unger","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2015.11.009_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4093\/dmj.2015.39.1.1","article-title":"Pancreatic \u03b1-cell dysfunction in type 2 diabetes: old kids on the block","volume":"39","author":"Moon","year":"2015","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.tips.2015.11.009_bib0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1758-5996-6-91","article-title":"The role of glucagon on type 2 diabetes at a glance","volume":"6","author":"Godoy-Matos","year":"2014","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.tips.2015.11.009_bib0195","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2337\/db12-1098","article-title":"Novel insights into the regulation of postprandial lipemia by glucagon-like peptides: significance for diabetes","volume":"62","author":"Watts","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2015.11.009_bib0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2007.04.172","article-title":"Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus","volume":"126","author":"Pastromas","year":"2008","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.tips.2015.11.009_bib0205","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3945\/an.113.004903","article-title":"Clinical considerations and mechanistic determinants of postprandial lipemia in older adults","volume":"5","author":"Karsanos","year":"2014","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.tips.2015.11.009_bib0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2796.1999.00548.x","article-title":"Postprandial lipoprotein metabolism and atherosclerosis","volume":"246","author":"Karpe","year":"1999","journal-title":"J. Int. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0215","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/dmr.5610030208","article-title":"Lipoprotein lipase in diabetes","volume":"3","author":"Taskinen","year":"1987","journal-title":"Diabetes Metab. Rev."},{"key":"10.1016\/j.tips.2015.11.009_bib0220","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cardiores.2005.09.017","article-title":"Cardiac lipoprotein lipase: metabolic basis for diabetic heart disease","volume":"69","author":"Pulinilkunnil","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.tips.2015.11.009_bib0225","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2015.11.009_bib0230","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/01.ATV.2.6.493","article-title":"Comparison of cholesteryl ester transfer from chylomicrons and other plasma lipoproteins to aorta intima-media of cholesterol-fed rabbits","volume":"2","author":"Stender","year":"1982","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.tips.2015.11.009_bib0235","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0021-9150(87)90020-7","article-title":"Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study","volume":"65","author":"Simmons","year":"1987","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tips.2015.11.009_bib0240","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11883-013-0309-9","article-title":"Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies","volume":"15","author":"Chan","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.tips.2015.11.009_bib0245","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2015.11.009_bib0250","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2015.11.009_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/S1262-3636(06)70482-7","article-title":"Postprandial endothelial dysfunction: role of glucose, lipids and insulin","volume":"32","author":"Nitenberg","year":"2006","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.tips.2015.11.009_bib0260","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1368-5031.2006.00825.x","article-title":"Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia","volume":"60","author":"Wright","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.tips.2015.11.009_bib0265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-3-319-07320-0_12","article-title":"Postprandial inflammation: targeting glucose and lipids","volume":"824","author":"de Vries","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tips.2015.11.009_bib0270","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/01.RES.80.6.819","article-title":"Lipoprotein lipase increases lipoprotein binding to the artery wall and increases endothelial layer permeability by formation of lipolysis products","volume":"80","author":"Rutledge","year":"1997","journal-title":"Circ. Res."},{"key":"10.1016\/j.tips.2015.11.009_bib0275","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ajcn\/85.1.60","article-title":"Postprandial monocyte activation in response to meals with high and low glycemic loads in overweight women","volume":"85","author":"Motton","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.tips.2015.11.009_bib0280","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11883-009-0031-9","article-title":"Inflammation associated with the postprandial lipolysis of triglyceride-rich lipoproteins by lipoprotein lipase","volume":"11","author":"Higgins","year":"2009","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.tips.2015.11.009_bib0285","first-page":"616","article-title":"Cardiovascular safety profile of currently available diabetic drugs","volume":"14","author":"Azimova","year":"2014","journal-title":"Ochsner J."},{"key":"10.1016\/j.tips.2015.11.009_bib0290","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","article-title":"Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes","volume":"36","author":"Ferrannini","year":"2015","journal-title":"Eur. Heart J."},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2015.11.009_bib0295","first-page":"65","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset, diabetes. V. Evaluation of pheniformin therapy","volume":"24","year":"1975","journal-title":"Diabetes"},{"key":"10.1016\/j.tips.2015.11.009_bib0300","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-157-9-201211060-00003","article-title":"Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study","volume":"157","author":"Roumie","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0305","first-page":"CD009008","article-title":"Sulphonylurea monotherapy for patients with type 2 diabetes mellitus","volume":"4","author":"Hemmingsen","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2015.11.009_bib0310","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.diabres.2013.05.010","article-title":"Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 diabetes: the DYDA study","volume":"101","author":"Cioffi","year":"2013","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tips.2015.11.009_bib0315","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1573399810666141030125830","article-title":"Glucagon-like peptide 1 and the cardiovascular system","volume":"10","author":"Fava","year":"2014","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.tips.2015.11.009_bib0320","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0325","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0330","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0335","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S2213-8587(15)00233-8","article-title":"Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis","volume":"3","author":"Fisher","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tips.2015.11.009_bib0340","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S2213-8587(15)00256-9","article-title":"Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists","volume":"3","author":"Scheen","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tips.2015.11.009_bib0345","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/dc10-1393","article-title":"Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database","volume":"34","author":"Best","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2015.11.009_bib0350","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0355","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"Nissen","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0360","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2015.11.009_bib0365","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1172\/JCI30335","article-title":"Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice","volume":"117","author":"Son","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2015.11.009_bib0370","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2015.11.009_bib0375","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bcp.12306","article-title":"Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis","volume":"78","author":"Turner","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2015.11.009_bib0380","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1161\/CIRCULATIONAHA.106.662296","article-title":"Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-\u03b1\/PGC-1\u03b1 gene regulatory pathway","volume":"115","author":"Duncan","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2015.11.009_bib0385","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI0214080","article-title":"The cardiac phenotype induced by PPAR\u03b1 overexpression mimics that caused by diabetes mellitus","volume":"109","author":"Finck","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2015.11.009_bib0390","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCULATIONAHA.109.888735","article-title":"Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-\u03b1 transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-\u03b1 activators","volume":"121","author":"Duncan","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.tips.2015.11.009_bib0395","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MOL.0b013e3283613a68","article-title":"Recent advances in niacin and lipid metabolism","volume":"24","author":"Kamanna","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.tips.2015.11.009_bib0400","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/MOL.0000000000000017","article-title":"Niacin: a long history, but a questionable future","volume":"24","author":"Ginsberg","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.tips.2015.11.009_bib0405","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2015.11.009_bib0410","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ahj.2014.03.021","article-title":"Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial","volume":"168","author":"Holman","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.tips.2015.11.009_bib0415","first-page":"415","article-title":"Ezetimibe therapy: mechanism of action and clinical update","volume":"8","author":"Phan","year":"2012","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.tips.2015.11.009_bib0420","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jjcc.2012.07.010","article-title":"Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load","volume":"60","author":"Hiramitsu","year":"2012","journal-title":"J. Cardiol."},{"key":"10.1016\/j.tips.2015.11.009_bib0425","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.atherosclerosis.2011.03.012","article-title":"Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes","volume":"217","author":"Bozzetto","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tips.2015.11.009_bib0430","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2008.04.035","article-title":"The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients","volume":"202","author":"Hajer","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tips.2015.11.009_bib0435","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.5551\/jat.12427","article-title":"Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia","volume":"19","author":"Kikuchi","year":"2012","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.tips.2015.11.009_bib0440","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.atherosclerosis.2011.04.019","article-title":"Ezetimibe improves postprandial hyperlipemia its induced endothelial F dysfunction","volume":"217","author":"Yunoki","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tips.2015.11.009_bib0445","doi-asserted-by":"crossref","first-page":"G1043","DOI":"10.1152\/ajpgi.00250.2011","article-title":"Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance","volume":"302","author":"Naples","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver. Physiol."},{"key":"10.1016\/j.tips.2015.11.009_bib0450","doi-asserted-by":"crossref","first-page":"914","DOI":"10.5551\/jat.4929","article-title":"Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia","volume":"17","author":"Sandoval","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.tips.2015.11.009_bib0455","doi-asserted-by":"crossref","first-page":"e0124587","DOI":"10.1371\/journal.pone.0124587","article-title":"Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Battagia","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2015.11.009_bib0460","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.amjmed.2015.01.034","article-title":"Ezetimibe plus moderate-dose simvastatin after acute coronary syndrome: what are we IMPROVEing on?","volume":"128","author":"DiNicolantonio","year":"2015","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0465","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijcha.2015.07.007","article-title":"Impact of combination therapy with statin and ezetimibe on secondary prevention for post-acute myocardial infarction patients in the statin era","volume":"8","author":"Ebisawa","year":"2015","journal-title":"IJC Heart & Vasculature"},{"key":"10.1016\/j.tips.2015.11.009_bib0470","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","article-title":"Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tips.2015.11.009_bib0475","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2015.04.121","article-title":"Simvastatin\u2013ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: a population-based dynamic cohort study","volume":"190","author":"Chang","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.tips.2015.11.009_bib0480","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1463-1326.2008.00970.x","article-title":"Orlistat 120mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss","volume":"11","author":"Jacob","year":"2009","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tips.2015.11.009_bib0485","doi-asserted-by":"crossref","first-page":"458","DOI":"10.5812\/ijem.2920","article-title":"Postprandial effect of orlistat on the peaking of lipid level after sequential high fat meals","volume":"10","author":"Gabriel","year":"2012","journal-title":"Int. J. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2015.11.009_bib0490","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.atherosclerosis.2004.11.023","article-title":"Effect of orlistat on postprandial lipemia NMR lipoprotein subclass profiles and particle size","volume":"180","author":"Suter","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tips.2015.11.009_bib0495","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tips.2015.11.009_bib0500","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1262-3636(07)70161-1","article-title":"The effects of orlistat on metabolic parameters and other cardiovascular risk factors","volume":"31","author":"Kiortsis","year":"2005","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.tips.2015.11.009_bib0505","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cmet.2014.07.013","article-title":"Control of gluconeogenesis by metformin: does redox trump energy charge?","volume":"20","author":"Baur","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.tips.2015.11.009_bib0510","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2015.11.009_bib0515","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","article-title":"Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials","volume":"13","author":"Lamanna","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tips.2015.11.009_bib0520","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2015.11.009_bib0525","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1262-3636(14)72689-8","article-title":"Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence","volume":"40","author":"Scheen","year":"2014","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.tips.2015.11.009_bib0530","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0535","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3904\/kjim.2001.16.2.87","article-title":"The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus","volume":"16","author":"Chang","year":"2001","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.tips.2015.11.009_bib0540","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.phrs.2007.04.007","article-title":"Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients","volume":"56","author":"Agrawal","year":"2007","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2015.11.009_bib0545","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1053\/meta.2002.35191","article-title":"Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus","volume":"51","author":"Ikewaki","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.tips.2015.11.009_bib0550","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.diabres.2010.09.009","article-title":"Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus","volume":"91","author":"Rhee","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tips.2015.11.009_bib0555","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0168-8227(00)00235-7","article-title":"Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus","volume":"52","author":"Ahn","year":"2001","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tips.2015.11.009_bib0560","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/j.1463-1326.2012.01632.x","article-title":"Pancreatic (-cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2 diabetes","volume":"14","author":"Muhammed","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tips.2015.11.009_bib0565","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10571-012-9896-1","article-title":"Cilostazol strengthens barrier integrity in brain endothelial cells","volume":"33","author":"Horai","year":"2013","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.tips.2015.11.009_bib0570","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mvr.2004.05.002","article-title":"Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production","volume":"68","author":"Omi","year":"2004","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.tips.2015.11.009_bib0575","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.HYP.0000158263.64320.eb","article-title":"Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F","volume":"45","author":"Kim","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.tips.2015.11.009_bib0580","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Eng. J. Med."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016561471500245X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016561471500245X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T18:51:36Z","timestamp":1537123896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016561471500245X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":116,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S016561471500245X"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2015.11.009","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2015.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}